Regulation of g protein-coupled receptors by allosteric ligands

ACS Chemical Neuroscience

Volumn 4, Issue 4, 2013, Pages 527-534

  Lane, J Robert ^a   Abdul Ridha, Alaa ^a   Canals, Meritxell ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

allosteric ligand; arrestin; endocytosis; functional selectivity; G protein coupled receptor

Indexed keywords

2 AMINO 4,5 DIMETHYL 3 (3 TRIFLUOROMETHYLBENZOYL)THIOPHENE; ALCURONIUM; BETA ARRESTIN; CHEMOKINE RECEPTOR CCR7; CHEMOKINE RECEPTOR CXCR4; FLURAZEPAM; G PROTEIN COUPLED RECEPTOR; GALLAMINE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ALLOSTERISM; BINDING AFFINITY; BINDING SITE; BRAIN CORTEX; BRAIN NERVE CELL; CELL SURFACE; DOWN REGULATION; DRUG DEVELOPMENT; ENDOCYTOSIS; HIPPOCAMPUS; INTERNALIZATION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

ALLOSTERIC REGULATION; ANIMALS; DRUG DISCOVERY; ENDOCYTOSIS; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84876525643     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn400005t     Document Type: Review

References (64)

1. Rask-Andersen, M., Almén, M. S., and Schiöth, H. B. (2011) Trends in the exploitation of novel drug targets Nat. Rev. Drug Discovery 10, 579-590
2. Christopoulos, A. (2002) Allosteric binding sites on cell-surface receptors: novel targets for drug discovery Nat. Rev. Drug Discovery 1, 198-210
3. Conn, P., Christopoulos, A., and Lindsley, C. (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders Nat. Rev. Drug Discovery 8, 41-54
4. Kenakin, T. and Miller, L. J. (2010) Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery Pharmacol. Rev. 62, 265-304
5. Stallaert, W., Christopoulos, A., and Bouvier, M. (2011) Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors Expert Opin. Drug Discovery 6, 811-825
6. Whalen, E. J., Rajagopal, S., and Lefkowitz, R. J. (2011) Therapeutic potential of β-arrestin- and G protein-biased agonists Trends Mol. Med. 17, 126-139
7. Rasmussen, S. G. F., Devree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., Mathiesen, J. M., Shah, S. T. A., Lyons, J. A., Caffrey, M., Gellman, S. H., Steyaert, J., Skiniotis, G., Weis, W. I., Sunahara, R. K., and Kobilka, B. K. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex Nature 477, 549-555
8. Cabrera-Vera, T. M., Vanhauwe, J., Thomas, T. O., Medkova, M., Preininger, A., Mazzoni, M. R., and Hamm, H. E. (2003) Insights into G protein structure, function, and regulation Endocr. Rev. 24, 765-781
9. Lefkowitz, R. J. and Whalen, E. J. (2004) beta-arrestins: traffic cops of cell signaling Curr. Opin. Cell Biol. 16, 162-168
10. DeWire, S. M., Ahn, S., Lefkowitz, R. J., and Shenoy, S. K. (2007) β-Arrestins and Cell Signaling Annu. Rev. Physiol. 69, 483-510
11. Murphy, J. E., Padilla, B. E., Hasdemir, B., Cottrell, G. S., and Bunnett, N. W. (2009) Endosomes: a legitimate platform for the signaling train Proc. Natl. Acad. Sci. U.S.A. 106, 17615-17622
12. May, L., Leach, K., Sexton, P., and Christopoulos, A. (2007) Allosteric modulation of G protein-coupled receptors Annu. Rev. Pharmacol. Toxicol. 47, 1-51
13. Dorr, P., Westby, M., Dobbs, S., Griffin, P., Irvine, B., Macartney, M., Mori, J., Rickett, G., Smith-Burchnell, C., Napier, C., Webster, R., Armour, D., Price, D., Stammen, B., Wood, A., and Perros, M. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity Antimicrob. Agents Chemother. 49, 4721-4732
14. Lindberg, J. S. (2005) Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal Dialysis: A Randomized, Double-Blind, Multicenter Study J. Am. Soc. Nephrol. 16, 800-807
15. Monod, J., Wyman, J., and Changeux, J.-P. (1965) On the nature of allosteric transitions: a plausible model J. Mol. Biol. 88-118
16. Canals, M., Lane, J. R., Wen, A., Scammells, P. J., Sexton, P. M., and Christopoulos, A. (2012) A Monod-Wyman-Changeux Mechanism Can Explain G Protein-coupled Receptor (GPCR) Allosteric Modulation J. Biol. Chem. 287, 650-659
17. Canals, M., Sexton, P. M., and Christopoulos, A. (2011) Allostery in GPCRs: "MWC" revisited Trends Biochem. Sci. 36, 663-672
18. Tallman, J. F., Thomas, J. W., and Gallager, D. W. (1978) GABAergic modulation of benzodiazepine binding site sensitivity Nature 274, 383-385
19. Sigel, E. and Buhr, A. (1997) The benzodiazepine binding site of GABAA receptors Trends Pharmacol. Sci. 18, 425-429
20. Jacob, T. C., Moss, S. J., and Jurd, R. (2008) GABA(A) receptor trafficking and its role in the dynamic modulation of neuronal inhibition Nat. Rev. Neurosci. 9, 331-343
21. Gassmann, M. and Bettler, B. (2012) Regulation of neuronal GABA(B) receptor functions by subunit composition Nat. Rev. Neurosci. 13, 380-394
22. Uusi-Oukari, M. and Korpi, E. R. (2010) Regulation of GABA(A) receptor subunit expression by pharmacological agents Pharmacol. Rev. 62, 97-135
23. Jacob, T. C., Michels, G., Silayeva, L., Haydon, J., Succol, F., and Moss, S. J. (2012) Benzodiazepine treatment induces subtype-specific changes in GABAA receptor trafficking and decreases synaptic inhibition Proc. Natl. Acad. Sci. U.S.A. 109, 18595-18600
24. Leach, K., Loiacono, R., Felder, C., McKinzie, D., Mogg, A., Shaw, D., Sexton, P., and Christopoulos, A. (2009) Molecular Mechanisms of Action and In Vivo Validation of an M4Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties Neuropsychopharmacology 35, 855-869
25. May, L. T., Lin, Y., Sexton, P. M., and Christopoulos, A. (2005) Regulation of M2 muscarinic acetylcholine receptor expression and signaling by prolonged exposure to allosteric modulators J. Pharmacol. Exp. Ther. 312, 382-390
26. Avlani, V. A., Gregory, K. J., Morton, C. J., Parker, M. W., Sexton, P. M., and Christopoulos, A. (2007) Critical role for the second extracellular loop in the binding of both orthosteric and allosteric G protein-coupled receptor ligands J. Biol. Chem. 282, 25677-25686
27. Davis, C., Bradley, S., Schiffer, H., Friberg, M., Koch, K., Tolf, B.-R., Bonhaus, D., and Lameh, J. (2009) Differential regulation of muscarinic M1 receptors by orthosteric and allosteric ligands BMC Pharmacol. 9, 9-14
28. Davis, A. A., Heilman, C. J., Brady, A. E., Miller, N. R., Fuerstenau-Sharp, M., Hanson, B. J., Lindsley, C. W., Conn, P. J., Lah, J. J., and Levey, A. I. (2010) Differential effects of allosteric M(1) muscarinic acetylcholine receptor agonists on receptor activation, arrestin 3 recruitment, and receptor downregulation ACS. Chem. Neurosci. 1, 542-551
29. Thomas, R. L., Langmead, C. J., Wood, M. D., and Challiss, R. A. J. (2009) Contrasting effects of allosteric and orthosteric agonists on m1 muscarinic acetylcholine receptor internalization and down-regulation J. Pharmacol. Exp. Ther. 331, 1086-1095
30. Ma, L., Seager, M. A., Seager, M., Wittmann, M., Jacobson, M., Bickel, D., Burno, M., Jones, K., Graufelds, V. K., Xu, G., Pearson, M., McCampbell, A., Gaspar, R., Shughrue, P., Danziger, A., Regan, C., Flick, R., Pascarella, D., Garson, S., Doran, S., Kreatsoulas, C., Veng, L., Lindsley, C. W., Shipe, W., Kuduk, S., Sur, C., Kinney, G., Seabrook, G. R., and Ray, W. J. (2009) Selective activation of the M1 muscarinic acetylcholine receptor achieved by allosteric potentiation Proc. Natl. Acad. Sci. U.S.A. 106, 15950-15955
31. i-independent ERK1/2 kinase activation J. Biol. Chem. 287, 12070-12082
32. Coopman, K., Huang, Y., Johnston, N., Bradley, S. J., Wilkinson, G. F., and Willars, G. B. (2010) Comparative effects of the endogenous agonist glucagon-like peptide-1 (GLP-1)-(7-36) amide and the small-molecule ago-allosteric agent "compound 2" at the GLP-1 receptor J. Pharmacol. Exp. Ther. 334, 795-808
33. 2 cells Proc. Natl. Acad. Sci. U.S.A. 105, 6614-6619
34. Pelkey, K. A., Yuan, X., Lavezzari, G., Roche, K. W., and McBain, C. J. (2007) mGluR7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082 Neuropharmacology 52, 108-117
35. Parmentier-Batteur, S., Obrien, J. A., Doran, S., Nguyen, S. J., Flick, R. B., Uslaner, J. M., Chen, H., Finger, E. N., Williams, T. M., Jacobson, M. A., and Hutson, P. H. (2012) Differential effects of the mGluR5 positive allosteric modulator CDPPB in the cortex and striatum following repeated administration Neuropharmacology 62, 1453-1460
36. Huang, Y. and Breitwieser, G. E. (2007) Rescue of calcium-sensing receptor mutants by allosteric modulators reveals a conformational checkpoint in receptor biogenesis J. Biol. Chem. 282, 9517-9525
37. Muniz-Medina, V. M., Jones, S., Maglich, J. M., Galardi, C., Hollingsworth, R. E., Kazmierski, W. M., Ferris, R. G., Edelstein, M. P., Chiswell, K. E., and Kenakin, T. P. (2009) The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property? Mol. Pharmacol. 75, 490-501
38. Spengler, D., Waeber, C., Pantaloni, C., Holsboer, F., Bockaert, J., Seeburg, P. H., and Journot, L. (1993) Differential signal transduction by five splice variants of the PACAP receptor Nature 365, 170-175
39. Tobin, A. B., Butcher, A. J., and Kong, K. C. (2008) Location, location, location...site-specific GPCR phosphorylation offers a mechanism for cell-type-specific signalling Trends Pharmacol. Sci. 29, 413-420
40. Butcher, A. J., Prihandoko, R., Kong, K. C., McWilliams, P., Edwards, J. M., Bottrill, A., Mistry, S., and Tobin, A. B. (2011) Differential G-protein-coupled receptor phosphorylation provides evidence for a signaling bar code J. Biol. Chem. 286, 11506-11518
41. Nobles, K. N., Xiao, K., Ahn, S., Shukla, A. K., Lam, C. M., Rajagopal, S., Strachan, R. T., Huang, T.-Y., Bressler, E. A., Hara, M. R., Shenoy, S. K., Gygi, S. P., and Lefkowitz, R. J. (2011) Distinct phosphorylation sites on the β(2)-adrenergic receptor establish a barcode that encodes differential functions of β-arrestin Sci. Signaling 4, ra51
42. Busillo, J., Armando, S., Sengupta, R., Meucci, O., Bouvier, M., and Benovic, J. (2010) Site-specific Phosphorylation of CXCR4 Is Dynamically Regulated by Multiple Kinases and Results in Differential Modulation of CXCR4 Signaling J. Biol. Chem. 285, 7805-7817
43. Zidar, D. A., Violin, J. D., Whalen, E. J., and Lefkowitz, R. J. (2009) Selective engagement of G protein coupled receptor kinases (GRKs) encodes distinct functions of biased ligands Proc. Natl. Acad. Sci. U.S.A. 106, 9649-9654
44. Ahn, S., Maudsley, S., Luttrell, L. M., Lefkowitz, R. J., and Daaka, Y. (1999) Src-mediated tyrosine phosphorylation of dynamin is required for beta2-adrenergic receptor internalization and mitogen-activated protein kinase signaling J. Biol. Chem. 274, 1185-1188
45. Tohgo, A., Pierce, K. L., Choy, E. W., Lefkowitz, R. J., and Luttrell, L. M. (2002) beta-Arrestin scaffolding of the ERK cascade enhances cytosolic ERK activity but inhibits ERK-mediated transcription following angiotensin AT1a receptor stimulation J. Biol. Chem. 277, 9429-9436
46. Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., and Lefkowitz, R. J. (2007) A unique mechanism of beta-blocker action: carvedilol stimulates beta-arrestin signaling Proc. Natl. Acad. Sci. U.S.A. 104, 16657-16662
47. Wei, H., Ahn, S., Shenoy, S. K., Karnik, S. S., Hunyady, L., Luttrell, L. M., and Lefkowitz, R. J. (2003) Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2 Proc. Natl. Acad. Sci. U.S.A. 100, 10782-10787
48. Gesty-Palmer, D., Flannery, P., Yuan, L., Corsino, L., Spurney, R., Lefkowitz, R. J., and Luttrell, L. M. (2009) A beta-arrestin-biased agonist of the parathyroid hormone receptor (PTH1R) promotes bone formation independent of G protein activation Sci. Transl. Med. 1, 1ra1
49. Kong, K. C., Butcher, A. J., McWilliams, P., Jones, D., Wess, J., Hamdan, F. F., Werry, T., Rosethorne, E. M., Charlton, S. J., Munson, S. E., Cragg, H. A., Smart, A. D., and Tobin, A. B. (2010) M3-muscarinic receptor promotes insulin release via receptor phosphorylation/arrestin-dependent activation of protein kinase D1 Proc. Natl. Acad. Sci. U.S.A. 107, 21181-21186
50. Quoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., and Dalle, S. (2010) GLP-1 mediates antiapoptotic effect by phosphorylating Bad through a beta-arrestin 1-mediated ERK1/2 activation in pancreatic beta-cells J. Biol. Chem. 285, 1989-2002
51. Masri, B., Salahpour, A., Didriksen, M., Ghisi, V., Beaulieu, J.-M., Gainetdinov, R. R., and Caron, M. G. (2008) Antagonism of dopamine D2 receptor/beta-arrestin 2 interaction is a common property of clinically effective antipsychotics Proc. Natl. Acad. Sci. U.S.A. 105, 13656-13661
52. Walters, R. W., Shukla, A. K., Kovacs, J. J., Violin, J. D., DeWire, S. M., Lam, C. M., Chen, J. R., Muehlbauer, M. J., Whalen, E. J., and Lefkowitz, R. J. (2009) beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice J. Clin. Invest. 119, 1312-1321
53. Bohn, L. M., Lefkowitz, R. J., and Caron, M. G. (2002) Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice J. Neurosci. 22, 10494-10500
54. Dang, V. C., Chieng, B., Azriel, Y., and Christie, M. J. (2011) Cellular Morphine Tolerance Produced by Arrestin-2-Dependent Impairment of -Opioid Receptor Resensitization J. Neurosci. 31, 7122-7130
55. Raehal, K. M., Schmid, C. L., Groer, C. E., and Bohn, L. M. (2011) Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance Pharmacol. Rev. 63, 1001-1019
56. Groer, C. E., Schmid, C. L., Jaeger, A. M., and Bohn, L. M. (2011) Agonist-directed interactions with specific arrestins determine μ-opioid receptor trafficking, ubiquitination, and dephosphorylation J. Biol. Chem. 286, 31731-31741
57. Kao, Y. J., Ghosh, M., and Schonbrunn, A. (2011) Ligand-dependent mechanisms of sst2A receptor trafficking: role of site-specific phosphorylation and receptor activation in the actions of biased somatostatin agonists Mol. Endocrinol. 25, 1040-1054
58. Atwood, B. K., Wager-Miller, J., Haskins, C., Straiker, A., and Mackie, K. (2012) Functional selectivity in CB(2) cannabinoid receptor signaling and regulation: implications for the therapeutic potential of CB(2) ligands Mol. Pharmacol. 81, 250-263
59. Leach, K., Sexton, P., and Christopoulos, A. (2007) Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology Trends Pharmacol. Sci. 28, 382-389
60. Klaasse, E., den Hout, van, G., Roerink, S., de Grip, W., Ijzerman, A., and Beukers, M. (2005) Allosteric modulators affect the internalization of human adenosine A1 receptors Eur. J. Pharmacol. 522, 1-8
61. Bhattacharya, S. and Linden, J. (1996) Effects of long-term treatment with the allosteric enhancer, PD81,723, on Chinese hamster ovary cells expressing recombinant human A1 adenosine receptors Mol. Pharmacol. 50, 104-111
62. Newton, C. L., Whay, A. M., McArdle, C. A., Zhang, M., van Koppen, C. J., van de Lagemaat, R., Segaloff, D. L., and Millar, R. P. (2011) Rescue of expression and signaling of human luteinizing hormone G protein-coupled receptor mutants with an allosterically binding small-molecule agonist Proc. Natl. Acad. Sci. U.S.A. 108, 7172-7176
63. Scholten, D. J., Canals, M., Wijtmans, M., de Munnik, S., Nguyen, P., Verzijl, D., de Esch, I. J. P., Vischer, H. F., Smit, M. J., and Leurs, R. (2012) Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3 Br. J. Pharmacol. 166, 898-911
64. Sachpatzidis, A., Benton, B. K., Manfredi, J. P., Wang, H., Hamilton, A., Dohlman, H. G., and Lolis, E. (2003) Identification of allosteric peptide agonists of CXCR4 J. Biol. Chem. 278, 896-907